Akebia Therapeutics, Inc. (AKBA)

Akebia Therapeutics' stock price has declined significantly over the past six months. Piper Sandler lowered its price target for AKBA in February 2026. Despite exceeding Q3 2025 revenue forecasts, the stock fell due to earnings per share missing expectations. The decision to refocus Vafseo on dialysis patients impacted the stock, and Q4 2025 net revenue for Vafseo was expected to be muted due to a channel inventory adjustment, with revenue growth projected to resume in Q1 2026.

The available information does not explicitly indicate demand seasonality for Akebia Therapeutics' products and services. Demand is primarily influenced by factors such as patient access, prescriber adoption, and adherence to treatment protocols rather than seasonal fluctuations. The company anticipates revenue normalization following temporary inventory reductions in Q4 2025, with revenue growth expected to resume in Q1 2026 due to increased patient access and anticipated improvements in adherence and compliance.

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for kidney diseases, operating within the Health Technology sector. Its product portfolio includes Auryxia, approved for controlling serum phosphorus levels in dialysis-dependent chronic kidney disease patients and treating iron deficiency anemia in non-dialysis dependent chronic kidney disease patients, and Vafseo, approved in Japan for treating anemia due to chronic kidney disease in dialysis patients. The company is also advancing pipeline candidates like AKB-9090 and AKB-10108.

Akebia Therapeutics is headquartered in Cambridge, Massachusetts, United States. It has collaborations with Otsuka Pharmaceutical for vadadustat in the U.S. and Mitsubishi Tanabe Pharma Corporation for Vafseo in Japan and other Asian countries. Akebia has broad prescribing access for Vafseo, covering approximately 275,000 U.S. dialysis patients.

Akebia Therapeutics is recognized as a trusted leader in the renal community. Analyst sentiment is generally positive, with a consensus rating of "Moderate Buy". Despite positive financial results in Q3 2025, the stock has experienced volatility, indicating mixed market sentiment.

Akebia Therapeutics has 304 institutional owners and shareholders, holding a total of 141,089,322 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and State Street Corp. Individual or retail investors hold a majority stake, and the company's CEO, John Butler, holds 0.6% of the shares.